Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8008660 | 0.84 | TSHR (0.56) | KMT2AMEN1CYP2C19TSHRMAPT | |
| SCHEMBL13197240 | 0.84 | POLB (0.45) | CYP1A2TSHRGAAALDH1A1HTT | |
| SCHEMBL29318769 | 0.82 | TSHR (0.53) | KMT2ACYP2C19TSHRMAPTALDH1A1 | |
| SCHEMBL7733270 | 0.81 | CYP2C19 (0.57) | KMT2AMEN1CYP2C19CYP1A2TSHR | |
| SCHEMBL43494 | 0.81 | CYP2C19 (0.57) | KMT2AMEN1CYP2C19CYP1A2TSHR | |
| SCHEMBL6932662 | 0.80 | CYP2C19 (0.61) | KMT2AMEN1CYP2C19CYP1A2TSHR | |
| SCHEMBL9911538 | 0.80 | TSHR (0.56) | CYP2C19CYP1A2TSHRALDH1A1HTT | |
| SCHEMBL1625876 | 0.79 | MEN1 (0.56) | KMT2AMEN1CYP2C19CYP1A2TSHR | |
| SCHEMBL1625595 | 0.79 | MEN1 (0.56) | KMT2AMEN1CYP2C19CYP1A2TSHR | |
| SCHEMBL1625885 | 0.79 | MEN1 (0.56) | KMT2AMEN1CYP2C19CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745280-B2 | Compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient | SNU R&DB FOUNDATION (KR) | 2017-08-29 | — | — | US | disclosed |
| US-9745280-B2 | Compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient | SNU R&DB FOUNDATION (KR) | 2017-08-29 | — | — | US | disclosed |
| US-9562186-B2 | Oligomeric and polymeric electronically-modified boronic acids and methods of using the same | HALLIBURTON ENERGY SERVICES, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160340331-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2016-11-24 | — | — | US | disclosed |
| US-20150210918-A1 | OLIGOMERIC AND POLYMERIC ELECTRONICALLY-MODIFIED BORONIC ACIDS AND METHODS OF USING THE SAME | HALLIBURTON ENERGY SERVICES, INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-9057698-B2 | Methods of chemoselective derivation of multiple classes of metabolites | BROWN UNIVERSITY (US) | 2015-06-16 | — | — | US | disclosed |
| US-9027644-B2 | Oligomeric and polymeric electronically-modified boronic acids and methods of using the same | HALLIBURTON ENERGY SERVICES, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140174748-A1 | OLIGOMERIC AND POLYMERIC ELECTRONICALLY-MODIFIED BORONIC ACIDS AND METHODS OF USING THE SAME | HALLIBURTON ENERGY SERVICES, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140110120-A1 | Oligomeric and Polymeric Electronically-Modified Boronic Acids and Methods of Using the Same | HALLIBURTON ENERGY SERVICES, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20130071940-A1 | METHODS OF CHEMOSELECTIVE DERIVATION OF MULTIPLE CLASSES OF METABOLITES | BROWN UNIVERSITY (US) | 2013-03-21 | — | — | US | disclosed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-7517998-B2 | Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2009-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340331-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | HSP90AB1, HSP90AA1, HSP90AB2P | KMT2A 3179/4885MEN1 4632/4885CYP2C19 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.